Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

We are thrilled to have John join the Nurix team as we prepare to launch our pivotal clinical program for NX-5948 in chronic lymphocytic leukemia and potentially other B-cell malignancies,” said ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...

Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist.

SAN FRANCISCO - Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in targeted protein modulation drugs, announced today the appointment of John Northcott as its new ...